MARKET

CYTK

CYTK

Cytokinetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.82
-0.60
-3.09%
Closed 16:00 03/03 EST
OPEN
19.36
PREV CLOSE
19.42
HIGH
19.98
LOW
18.56
VOLUME
537.35K
TURNOVER
--
52 WEEK HIGH
30.14
52 WEEK LOW
8.00
MARKET CAP
1.34B
P/E (TTM)
-9.3367
1D
5D
1M
3M
1Y
5Y
Insider Trends: Cytokinetics Insider Sale for Taxes Adds to 90-Day Selling Trend
MT Newswires · 22h ago
Insider Trends: Cytokinetics Insider Continues Selling Trend with Tax Sale
MT Newswires · 22h ago
Cytokinetics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the virtual H.C. Wainwright Global Life Science...
GlobeNewswire · 1d ago
Spinal Muscular Atrophy (SMA) Treatment Market Size, Share, Growth, Research and Forecast 2019-2025
Mar 02, 2021 (Market Insight Reports) -- The global spinal muscular atrophy (SMA) treatment market is projected to exhibit considerable growth during the...
Market Insight Reports · 2d ago
Acute Heart Failure (AHF) Therapeutics Market Report 2021 Industry Size, Market Status, Influencing Factors, Competition, SWOT Analysis, Outlook and 2027 Forecast
Mar 02, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Acute Heart Failure (AHF)...
The Express Wire · 2d ago
8-K: CYTOKINETICS INC
(EDGAR Online via COMTEX) -- 0001061983 false 0001061983 2021-02-26 2021-02-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 5d ago
10-K: CYTOKINETICS INC
(EDGAR Online via COMTEX) -- ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion and analysis...
Edgar Online - (EDG = 10Q, 10K) · 5d ago
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Feb 26, 2021 (GLOBE NEWSWIRE via COMTEX) -- SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Cytokinetics,...
GlobeNewswire · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CYTK. Analyze the recent business situations of Cytokinetics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CYTK stock price target is 27.10 with a high estimate of 41.00 and a low estimate of 21.00.
EPS
Institutional Holdings
Institutions: 292
Institutional Holdings: 74.85M
% Owned: 105.26%
Shares Outstanding: 71.11M
TypeInstitutionsShares
Increased
58
5.76M
New
79
8.21M
Decreased
56
9.61M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Independent Director
Leonard Patrick Gage
Chief Executive Officer/President/Director
Robert Blum
Chief Financial Officer/Senior Vice President
Ching Jaw
Chief Human Resource Officer/Chief Administrative Officer
David Cragg
Executive Vice President
Fady Malik
Senior Vice President/General Counsel/Secretary
Mark Schlossberg
Chief Accounting Officer/Vice President
Robert Wong
Independent Director
Muna Bhanji
Independent Director
Robert Califf
Independent Director
Santo Costa
Independent Director
John Henderson
Independent Director
Edward Kaye
Independent Director
B. Lynne Parshall
Independent Director
Sandford Smith
Independent Director
Wendall Wierenga
Independent Director
Nancy Wysenski
No Data
  • All
  • Financials
  • Insiders
More
About CYTK
Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Company is developing small molecule drug candidates, which are specifically engineered to enhance muscle function and contractility. Its lead drug candidates in clinical development are: omecamtiv mecarbil, a cardiac myosin activator; AMG 594, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.

Webull offers kinds of Cytokinetics, Inc. stock information, including NASDAQ:CYTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYTK stock methods without spending real money on the virtual paper trading platform.